D64.4
Congenital dyserythropoietic anemia
Clinical Classification Guidelines
Inclusion Terms
- Dyshematopoietic anemia (congenital)
Excludes Type 1
- Blackfan-Diamond syndrome (D61.01)
- Di Guglielmo's disease (C94.0)
Medical Intelligence & Overview
Congenital dyserythropoietic anemia (CDA) is a rare inherited blood disorder characterized by the abnormal development of red blood cells in the bone marrow. This condition results in a shortage of healthy red blood cells, leading to anemia. The disorder is present from birth, and its severity can vary among individuals. People with CDA often experience symptoms related to anemia, such as fatigue and pallor, due to the decreased oxygen-carrying capacity of their blood. Understanding this condition is essential for proper diagnosis and management, although treatment approaches typically focus on alleviating symptoms and preventing complications.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting the development and maturation of erythrocytes (red blood cells) Inheritance patterns can be autosomal dominant or autosomal recessive depending on the specific subtype No environmental or acquired factors cause CDA; it is a congenital disorder Mutations often involve genes regulating erythropoiesis, the process of producing red blood cells
Key Symptoms: Mild to severe anemia leading to fatigue and weakness Pallor of the skin and mucous membranes Jaundice (yellowing of the skin and eyes) due to increased breakdown of abnormal red blood cells Splenomegaly (enlarged spleen), which may cause abdominal discomfort Bone marrow abnormalities visible under microscopic examination Delayed growth and development in some cases
Diagnostic & Treatment
Diagnosis Path: Diagnosis of congenital dyserythropoietic anemia involves multiple steps, including: - Complete blood counts (CBC) to evaluate red blood cell levels - Peripheral blood smear examination revealing characteristic abnormal red blood cell morphology - Bone marrow biopsy showing ineffective erythropoiesis and cellular abnormalities - Genetic testing to identify specific mutations associated with CDA - Exclusion of other causes of anemia such as acquired hematologic disorders Additional tests, such as bilirubin levels or iron studies, may also be conducted to assess hemolysis and iron status.
Treatment Protocols: There is no cure for CDA, and management aims to alleviate symptoms and prevent complications. Treatment options may include: - Regular blood transfusions when anemia is severe - Iron chelation therapy to remove excess iron resulting from repeated transfusions - Folic acid supplementation to support red blood cell production - Splenectomy (removal of the spleen) in cases of significant splenomegaly, which can reduce hemolysis - Monitoring and managing iron overload, a potential complication of transfusions - Supportive care and routine follow-up with a hematologist Research into targeted therapies is ongoing, and treatment plans are tailored based on individual disease severity and response.
Clinical Advice & FAQs
Billing Guidance
Is D64.4 a billable ICD-10 code?
Yes, D64.4 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D64.4?
Clinical documentation must specify the nature of Congenital dyserythropoietic anemia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference